News
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12 D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
19+ hour, 41+ min ago (715+ words) marketscreener. com...
Bicycle Therapeutics: April 2026 Corporate Presentation
2+ hour, 17+ min ago (1249+ words) Published on 04/20/2026 at 07: 24 am EDT Developing Bicycle" molecules - a novel synthetic peptide modality that can potentially deliver any payload to any target Focused on oncology, with multiple clinical molecules Nuzefatide pevedotin (formerly BT5528) targeting historically undruggable target with ADCs, progressing into…...
Newcelx updates corporate presentation to highlight type 1 diabetes flagship program
1+ hour, 39+ min ago (27+ words) marketscreener. com Biotechnology & Medical Research Newcelx updates corporate presentation to highlight type 1 diabetes flagship program...
Astrazeneca Says Tozorakimab Significantly Lowers COPD in Phase 3 Study
4+ hour, 53+ min ago (53+ words) marketscreener. com Astrazeneca Says Tozorakimab Significantly Lowers COPD in Phase 3 Study Published on 04/20/2026 at 04: 47 am EDT Latest news about Astra Zeneca PLC Income Statement and Estimates Astra Zeneca: Strengths remain aptly valued March 06, 2026 at 12: 58 pm EST...
Astra Zeneca's Tozorakimab meets primary endpoint in "pivotal" trial
5+ hour, 21+ min ago (198+ words) Published on 04/20/2026 at 04: 20 am EDT (Alliance News) - Astra Zeneca PLC on Monday reported positive phase three results for its monoclonal antibody, Tozorakimab, meeting its primary endpoint in the Miranda trial in patients with chronic obstructive pulmonary disease. The Cambridge, England-based…...
Lundbeck highlights cognitive improvements in migraine treatment according to study
8+ hour, 8+ min ago (150+ words) marketscreener. com Danish pharmaceutical company Lundbeck is presenting new real-world data from the INFUSE study at AAN 2026 The results indicate that migraine patients report improved cognitive symptoms, such as brain fog and difficulty concentrating, following treatment with eptinezumab. Over 50 percent…...
Astra Zeneca's tozorakimab delivers sharp reduction in COPD flare-ups
7+ hour, 28+ min ago (51+ words) marketscreener. com Astra Zeneca's tozorakimab delivers sharp reduction in COPD flare-ups Published on 04/20/2026 at 02: 13 am EDT Latest news about Astra Zeneca PLC Income Statement and Estimates Astra Zeneca: Strengths remain aptly valued March 06, 2026 at 12: 58 pm EST...
Astrazeneca says tozorakimab meets primary endpoint in phase III Miranda trial for COPD
6+ hour, 33+ min ago (59+ words) marketscreener. com Astrazeneca says tozorakimab meets primary endpoint in phase III Miranda trial for COPD Published on 04/20/2026 at 03: 07 am EDT Latest news about Astra Zeneca PLC Income Statement and Estimates Astra Zeneca: Strengths remain aptly valued March 06, 2026 at 12: 58 pm EST...
Australia's Monash IVF rejects another takeover offer from consortium
14+ hour, 39+ min ago (27+ words) marketscreener. com Monash IVF Group Limited Healthcare Facilities & Services Australia's Monash IVF rejects another takeover offer from consortium...
Study shows Sanofi's Nuvaxovid better tolerated than Moderna's m NEXSPIKE
8+ hour, 27+ min ago (77+ words) At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Sanofi presented positive data regarding Nuvaxovid, its protein-based, non-m RNA COVID-19 vaccine. Published on 04/20/2026 at 01: 14 am EDT Sanofi: Treatment for re-rating isn't easy April 07, 2026 at…...